echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Let the "beautiful killer" no longer run rampant

    Let the "beautiful killer" no longer run rampant

    • Last Update: 2022-03-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On-site group photo (Photo provided by the center)

    The 5-year survival rate of patients is 93.


    Breast cancer is also known as the "pink killer"


    Facing the huge number of breast cancer patients in China, it is urgent to have the diagnosis and treatment force with the international frontier level


    "Twenty years after the establishment of the center, we have gradually moved from following and running to leading


    The multi-disciplinary diagnosis and treatment model has a remarkable therapeutic effect

    Since 1952, Professor Li Yueyun, one of the founders of Fudan University Affiliated Cancer Hospital, has carried out breast cancer treatment earlier in China


    According to statistics, in 2021, the number of breast surgery outpatient visits will exceed 296,000, and the number of breast cancer surgeries will reach more than 8,100, accounting for more than 40% of the total of similar surgeries in Shanghai, ranking first in the country and leading the world


    The continuous development of breast surgery in the hospital has also led to the common development of other disciplines, including radiotherapy, internal medicine, imaging, pathology and other teams have made remarkable achievements


    Accurate diagnosis and treatment of "most difficult to treat" breast cancer

    As breast cancer diagnosis and treatment enter the era of molecular targeting, medical scientists classify breast cancer into different subtypes according to the different characteristics of breast cancer cells, and explore precise diagnosis and treatment strategies


    Especially for refractory breast cancer, the center has developed a set of "combination punches"


    Since then, the center has proposed a "Chinese plan" for triple-negative breast cancer combined with capecitabine adjuvant chemotherapy, which significantly improved the 5-year disease-free survival rate of triple-negative breast cancer patients and effectively reduced the risk of recurrence by 41%


    For the preoperative neoadjuvant treatment of HER2-positive breast cancer, the center has carried out research to confirm that the "strong combination" dual-target neoadjuvant treatment regimen of two tumor-targeted drugs, trastuzumab and pertuzumab, can improve breast cancer.


    While continuously improving the quality of clinical research, the center pays more attention to the establishment of basic and translational research systems


    Relevant research results have been successively published in authoritative journals such as "Cell Research" and "Cancer Cancer"


    Realize the whole process of breast cancer management

    With the continuous efforts of multidisciplinary talents, the center has now become one of the important teams in the field of international breast cancer diagnosis and treatment, and has continuously issued "Chinese voice" and introduced "Chinese standards" on the domestic and international stage


    Shao Zhimin said that with the development of diagnostic methods and the improvement of the level of diagnosis and treatment, breast cancer has become a preventable and treatable "chronic disease"


    However, the huge high-risk, new-onset population of breast cancer and a large number of breast cancer patients in the recovery follow-up period still face many difficulties: how to prevent breast cancer? How to choose a breast cancer diagnosis and treatment plan? How to manage breast cancer recovery period?

    To this end, in addition to opening specialized outpatient clinics to meet the needs of breast cancer patients for postoperative follow-up, dispensing, and dressing changes, the center integrates the concept of "full management" with "Internet +" technology to leverage the process of breast cancer chronic disease management.


    For example, through the establishment of the country's first whole-process breast cancer diagnosis and treatment platform - "Yankang e-follow-up", we have created an "online + offline" "full-course management of breast cancer"; by holding the Shanghai Breast Cancer Rehabilitation Forum, we have helped breast cancer patients both physically and mentally.
    Health and comprehensive recovery; and for the secondary upper limb lymphedema after breast cancer surgery, the center also opened a special clinic for lymphedema assessment, which met the needs of patients to a greater extent.
    .
    .


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.